19 September 2017 | News
Within the framework of the license agreement, there will be transfer of technology for the production of both ready-made forms and active pharmaceutical substances
The National Immunobiological Company (Nacimbio) which is a part of Rostec State Corporation has signed an agreement with Mylan Laboratories limited on the transfer of technology for the production of ready-made dosage forms and active pharmaceutical substances.
The agreement was signed at Biotechmed-2017 recently held in Gelendzhik. It is organised with the support of the Ministry of Health of the Russian Federation, the Ministry of Industry and Trade of the Russian Federation and the Ministry of Agriculture of the Russian Federation. The strategic partner of the conference is Rostec State Corporation.
Within the framework of the license agreement, there will be transfer of technology for the production of both ready-made forms and active pharmaceutical substances for the creation of modern combined drugs for the treatment of HIV infection.
At "Biotechmed-2017" conference Sergei Chemezov, CEO, Rostec said, “The Corporation's activities are aimed at reducing dependence on imported medicines. At the same time, the corporation is ready for a technological partnership in the pharmaceutical industry. "We are developing our own drug production, jointly with well-known foreign pharmaceutical companies, who are ready to localize production of their products in Russia.”
"We are starting cooperation with India's MYLAN LABORATORIES LIMITED. This will provide us with the supply of substances, transfer of technology and the creation of modern combination drugs for HIV treatment. As a result, their cost in the Russian market will significantly decrease”, he added.
Currently, Nacimbio supplies domestic vaccines under state contracts with the Ministry of Health, which are included in the national calendar of preventive vaccinations. In total, 17 items of vaccines are supplied, of which 14 are completely Russian-made.